TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01378676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A)
Description: Placebo tablets once daily for 14 days (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A)
Description: Placebo tablets once daily for 14 days (Part A)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A)
Description: Placebo tablets once daily for 14 days (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part A)
Description: One 125 mg CK-2017357 tablet once daily for 14 days (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part A)
Description: Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part A)
Description: Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG (Part B)
Description: One 50 mg tablet once daily for 14 days (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG (Part B)
Description: One 50 mg tablet once daily for 14 days (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG (Part B)
Description: One 50 mg tablet once daily for 14 days (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole 50 MG (Part B)
Description: One 50 mg tablet once daily for 14 days (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part B)
Description: Placebo tablets once daily for 14 days (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part B)
Description: Placebo tablets once daily for 14 days (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part B)
Description: Placebo tablets once daily for 14 days (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part B)
Description: One 125 mg tablet once daily for 14 days (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part B)
Description: Two 125 mg tablets once daily for 14 days (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part B)
Description: Three 125 mg tablets once daily for 14 days (Part B)
Study: NCT04770025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-density transcranial alternating current stimulation
Description: High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: High-density electrode configuration with sham stimulation

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motivational interviewing
Description: Motivational interviewing session focused on alcohol use, approximately 30 minutes in length

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing session focused on alcohol use, approximately 30 minutes in length

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing
Description: Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
Study: NCT03827070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (\<5 μm) - only 19%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcum powder
Description: Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (\<5 μm) - only 11%
Study: NCT02462811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
Study: NCT01922518

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septal pacing
Description: Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apex pacing
Description: Put RV lead around the apex
Study: NCT00877227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)
Description: Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
Study: NCT01281774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: reconstituted high density lipoprotein

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9%)
Study: NCT02311140

Intervention type: OTHER
Intervention: nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms
Study: NCT01153568

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 3
Description: Patients will bew given a single capsule to take once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets
Study: NCT01560754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal patch
Description: Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine transdermal patch
Description: Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
Study: NCT00088595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide (SOM230)
Description: Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
Study: NCT02982772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Intervention
Description: Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks
Study: NCT02686632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palatal brushing
Description: Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
Study: NCT00822120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD regimen
Study: NCT00100256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhenium (Re 188 P2045, BAY86-5284)
Description: Infusion once only
Study: NCT04619238

Intervention type: DIAGNOSTIC_TEST
Intervention: King's Health Questionnaire
Description: patients fulfilled questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: King's Health Questionnaire
Description: patients fulfilled questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: King's Health Questionnaire
Description: patients fulfilled questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: King's Health Questionnaire
Description: patients fulfilled questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: King's Health Questionnaire
Description: patients fulfilled questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form
Description: patients fulfilled ICIQ-SF questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form
Description: patients fulfilled ICIQ-SF questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form
Description: patients fulfilled ICIQ-SF questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form
Description: patients fulfilled ICIQ-SF questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form
Description: patients fulfilled ICIQ-SF questionnaire
Study: NCT02222688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab
Study: NCT00040781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03739099

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions
Description: Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data

Intervention type: DEVICE
Group type: OTHER
Intervention: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions
Description: Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
Study: NCT00040781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00822120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP regimen
Study: NCT03927547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclined Sleep
Description: Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
Study: NCT03245554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
Study: NCT00487773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: salbutamol
Study: NCT02817191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylo-Comod eye drop
Description: The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte eye drop
Description: The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
Study: NCT00822120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT00482612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
Study: NCT00822120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Study: NCT00482612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
Study: NCT03804047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: kinesio tape
Description: kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
Study: NCT02380677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301
Study: NCT02414750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus cobimetinib
Description: Molecular targeted therapy for BRAF mutated advanced melanoma patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue sampling
Description: Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Before and during treatment and at time of progression patients will undergo blood sampling
Study: NCT01837615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photopill treatment
Study: NCT03841513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Burch Colposuspension
Description: The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
Study: NCT04381403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-descaling D-Tart toothpaste
Description: Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crest® toothpaste
Description: Patients received Crest toothpaste; Anti-tartar toothpaste
Study: NCT00822120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00458198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated behavioral therapy (BT)
Description: Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
Study: NCT00822120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study: NCT01530178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: In each intervention arm the participant receives a different dose of sitagliptin.
Study: NCT00458198

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated behavioral therapy (BT)
Description: Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
Study: NCT00670683

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT01530178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: In each intervention arm the participant receives a different dose of sitagliptin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: In each intervention arm the participant receives a different dose of sitagliptin.
Study: NCT00822120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study: NCT03519425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised HIV screening and linkage to care
Description: As described in group descriptions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised HIV screening and linkage to care
Description: As described in group descriptions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised tuberculosis screening and linkage to care
Description: As described in group descriptions
Study: NCT01599234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
Study: NCT01378078

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eldith DC-stimulator (neuroconn, Ilmenau, Germany)
Description: daily tDCS treatment over left DLPFC, 20 min, 2 mA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eldith DC-stimulator (Neuroconn, Ilmenau, Germany)
Description: same as sham stimulation
Study: NCT00822120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT02033694

Intervention type: DEVICE
Intervention: NIRS-IVUS Imaging (TVC Imaging System)
Description: Diagnostic Imaging Catheter
Study: NCT01530178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT02227433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin